Jenburkt Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022, to consider and approve audited standalone financial results for the quarter and financial year ended on 31.03.2022 and to consider the recommendation of dividend, if any.
The above information is a part of company’s filings submitted to BSE.